Загрузка...
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
BACKGROUND: Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono‐ or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impa...
Сохранить в:
| Опубликовано в: : | Cochrane Database Syst Rev |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485963/ https://ncbi.nlm.nih.gov/pubmed/23152253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD008079.pub2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|